About alvotech - ALVO
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
ALVO At a Glance
Alvotech
9, rue de Bitbourg
Luxembourg, Luxembourg 1273
| Phone | 352-422-4500 | Revenue | 586.32M | |
| Industry | Biotechnology | Net Income | 27.92M | |
| Sector | Health Technology | 2025 Sales Growth | 19.735% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,460 | |
| View SEC Filings |
ALVO Valuation
| P/E Current | 33.195 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 53.216 |
| Price to Sales Ratio | 2.549 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 24.423 |
| Enterprise Value to Sales | 4.727 |
| Total Debt to Enterprise Value | 0.523 |
ALVO Efficiency
| Revenue/Employee | 401,589.726 |
| Income Per Employee | 19,122.603 |
| Receivables Turnover | 3.813 |
| Total Asset Turnover | 0.433 |
ALVO Liquidity
| Current Ratio | 1.888 |
| Quick Ratio | 1.164 |
| Cash Ratio | 0.567 |
ALVO Profitability
| Gross Margin | 57.116 |
| Operating Margin | 12.898 |
| Pretax Margin | 23.255 |
| Net Margin | 4.762 |
| Return on Assets | 2.062 |
| Return on Equity | N/A |
| Return on Total Capital | 2.397 |
| Return on Invested Capital | 3.017 |
ALVO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 124.427 |
| Total Debt to Total Assets | 97.448 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 120.219 |